Swedish precision radiation therapy leader Elekta has officially introduced its latest CT-based linear accelerator, Evo, to the Indian market, bringing high-definition AI-enhanced imaging and advanced adaptive radiation therapy capabilities to clinicians across the country.
The Evo system, which has already been successfully launched in Europe and several other regions, was announced for India through a company statement issued on Monday. The platform combines superior soft-tissue visualisation with the flexibility to deliver both conventional and highly personalised treatment plans, enabling radiation oncologists to select the most appropriate technique for each patient, whether standard fractionation, hypofractionation, or real-time adaptive therapy.
Evo made its Indian debut at the Association of Radiation Oncologists of India Conference (AROICON) in Kolkata, where it attracted significant interest from oncologists, medical physicists, and healthcare administrators.
Feras Al Hasan, Head of Turkey, India, Middle East & Africa (TIMEA) at Elekta, highlighted the system’s unique ability to support both online and offline adaptive treatments on a single CT-Linac platform. “Its ability to support both online and offline adaptive treatments on a CT-Linac gives clinicians the confidence to adjust therapy based on daily anatomical changes, which is especially important in India, where many patients present with complex and advanced-stage diseases,” he said. Al Hasan added that the launch reinforces Elekta’s commitment to making high-quality cancer treatment accessible to more patients worldwide.
Shankar Seshadri, Vice President & Head of the India Sub-continent at Elekta, emphasised the practical relevance of the technology for the local healthcare landscape. “India needs radiotherapy solutions that combine precision with practicality, and Evo is uniquely positioned to address India’s growing cancer burden and evolving patient needs,” he stated.
With approximately 1.4 million new cancer cases diagnosed in India each year and a large proportion presenting at advanced stages, the capability to adapt treatment plans in response to tumor shrinkage, weight loss, or organ motion can significantly improve outcomes while sparing healthy tissue. Evo’s AI-driven high-definition imaging, seamless plan adaptation workflow, reduced treatment margins, and compatibility with emerging stereotactic and ultra-hypofractionated regimens make it particularly well-suited for high-volume departments as well as premier academic centers.
The commercial availability of Evo in India marks another milestone in Elekta’s long-standing presence in the country and underscores its focus on delivering cutting-edge yet practical solutions that can elevate the standard of precision cancer care across the sub-continent.
Shankar Seshadri, its VP & Head - India Sub-continent, added: "India needs radiotherapy solutions that combine precision with practicality and Evo is uniquely positioned to address India's growing cancer burden and evolving patient needs."
Also Read: China’s factory activity contracts, trade truce notwithstanding
Follow us
